PTGX stock: buy or sell?

PTGX stock price: $7.52 1.21% At close on January 24th, 2020

Updated on:
January 24th, 2020


Protagonist shares gained 1.21% to $7.52 yesterday.

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based chemical entities to address various unmet medical needs.

Should I buy PTGX stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. That's why is so important to choose your own trading strategy that matches with your character as inversor. At, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Protagonist stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Protagonist Therapeutics stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At, we collected 2 ratings published for PTGX stock in the last 30 days.

Is PTGX a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-7-8HC Wainwrightn/aBuy
2019-2-22BMO Capital Marketsn/aOutperform

PTGX stock analysis

Daily outlook

Shares of Protagonist Therapeutics gained a fine 1.21% and closed at $7.52.

Protagonist Therapeutics gained a fine 1.21% and closed at $7.52. Since price and SMA200d lines crossed down on November, PTGX fell $-4.08 per share (-35.17%). From a daily perspective, PTGX is in a short term uptrend after plotting its last bottom ($6.64, on January 14th) higher than the previous bottom, and its last top ($7.66, on Wednesday) also over the previous top. Now trading in between its last bottom and last top PTGX might consolidate in a plain range, waiting to break out over $7.66 or down under $6.64.

PTGX stock chart (daily)

Weekly outlook

After boosting a brilliant 5.07% in a week last week, Protagonist Therapeutics closed this week at $7.52 and jumped an excellent 3.01%. This week was the third green week in a row. Late December 2019 PTGX plunged a hair-raising -6.22% in just one week.

Since price and 40-weeks moving average lines crossed down early November, PTGX fell $-5.93 per share (-44.09%). Stocks below the 200 days moving average line are usually not recommended for average traders.

PTGX stock chart (weekly)

PTGX stock price history

PTGX IPO was on August 11th, 2016 at $12.00 per share1. Since then, PTGX stock declined a -37.30%, with a yearly average of -12.40%.

1: Adjusted price after possible price splits or reverse-splits.

PTGX stock historical price chart

PTGX stock reached 52-week highs on September at $16.67, and all-time highs 2016-12-06 with a price of 26.36.

PTGX stock price target is $20.00

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. We have 2 price predictions for PTGX stock released in the last 30 days:
PTGX stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-7-8HC WainwrightInitiatesn/a$23.00-
2019-2-22BMO Capital MarketsInitiatesn/a$17.00-
(in average)$0.00$20.000.0%
Moving in a range from $23.00 and $17.00, the price forecast for PTGX stock is $20.00. In average, analysts' outlook on PTGX price forecast is stable from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On March, Protagonist Therapeutics presented its financial report, posting a super good growth for the Earnings per Share (EPS). Experts were expecting $-0.42 per share, but Protagonist posted $-0.57.
PTGX earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual turnover report draw an astounding growth of 54.14% to $30.93 million dollars. When comparing 2018 vs 2017, aligned with this, profit margin (that is, the net income divided by revenues) climbed a 58.34% to -125.87%.

PTGX annual Sales and Income evolution
2017$20 M-$-36.96 M-184.2%-
2018$31 M54.14%$-38.92 M-125.9%5.32%

Quarterly financial results

Protagonist Therapeutics reported $2.35 million in revenues for 2018-Q4, a -61.53% decline compared to previous quarter. Reported quarter income marked $-13.87 M with a profit margin of -589.25%. Profit margin plummed a -446.45% compared to previous quarter when profit margin was -142.80%. When comparing turnover to same quarter last year, Protagonist sales marked a frightening correction and plunged a -79.14%. Looking back to recent quarterly results, Protagonist posted 2 negative quarters in a row.
PTGX quarterly Sales and Income evolution
2017-Q3$9 M-$-4.83 M-54.9%-
2017-Q4$11 M28.48%$-3.05 M-27.1%-36.75%
2018-Q1$11 M-4.44%$-7.66 M-71.1%151.02%
2018-Q2$12 M8.28%$-8.66 M-74.2%13.08%
2018-Q3$6 M-47.60%$-8.74 M-142.8%0.83%
2018-Q4$2 M-61.53%$-13.87 M-589.2%58.73%

Protagonist ownership

When you are planning to buy a company, it's worth to overview its ownership structure.

Protagonist shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 4.59% of all shares.

Bearish positions for PTGX stock account 0.00%, no big difference from last month.

For a better context understanding, the following table shows ownership data compared to other related companies:

Market cap$204.6 M
Total shares27.2 M
Float shares15.0 M
  - Institutional holdings (%)89.2%
  - Insider holdings (%)4.6%
Shares in short selling0.0%

PTGX summary

Friday, January 24th, 2020
Day range$7.38 - $7.70
Previous close$7.43
Session gain1.21%
Average true range$0.38
50d mov avg$7.85
100d mov avg$10.35
200d mov avg$10.82
Daily patternlt06a
Weekly pattern lt11a

Protagonist performance

To measure stock performance is always good to compare with competitors or related stocks. We compared Protagonist Therapeutics against in the following table:
PTGXProtagonist Thera...-37.44%-35.89%-6.00%

Protagonist competitors

Unfortunately, we could not find any public company that could be defined as Protagonist competitor. This doesn't mean Protagonist does not have any competitor in the market, it's just we could not detected it.